Proteomics in Small Cell Lung Cancer

Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05623956

Acronym

SCLC-OMICS

Enrollment

Registered

2022-11-21

Start date

2023-03-01

Completion date

2025-12-31

Last updated

2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Keywords

Proteomics, Biomarkers

Brief summary

The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.

Detailed description

The study will include 50 patients with newly diagnosed SCLC, referred to systemic antineoplastic treatment at the Dept. of Oncology, Aalborg University Hospital and blood samples from 50 healthy blood donors. The blood samples from SCLC patients will be collected before chemotherapy with Carboplatin and Etoposide and after 2 cycles of chemotherapy. Imaging will be performed at the Dept. of Radiology, Aalborg University Hospital before chemotherapy and after 3 cycles of the treatment.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Written and signed informed consent * Histopathologically and/or cytologically newly-diagnosed SCLC * Measurable disease on CT scans * Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide

Exclusion criteria

* Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * Treatment with any other investigational agent

Design outcomes

Primary

Measure	Time frame	Description
Identification and validation of protein biomarkers	3 years	For identification and validation of protein biomarkers both untargeted and targeted proteomics will be performed, including a discovery-based bottom-up mass spectrometry approach and label-free Quantification Nano Liquid Chromatography Tandem Mass Spectrometry (LFQ nLC-MS/MS), enzyme-linked immunosorbent assay (ELISA)-based proteomics, and Western Blot analyses.

Countries

Denmark

Contacts

Primary ContactBorgen Dalsgaard

anbd@rn.dk97606989

Outcome results